OncoMatch/Clinical Trials/NCT06929936
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
Is NCT06929936 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Trilaciclib combined with Docetaxel for non-small cell lung cancer.
Treatment: Trilaciclib combined with Docetaxel — This study is a prospective, single arm phase II study aimed at patients with locally advanced or metastatic non-small cell lung cancer undergoing second-line or beyond treatment. The aim is to evaluate the bone marrow protective effect of trilaciclib before docetaxel chemotherapy for locally advanced or metastatic NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
Patients with negative driver genes must have received first line standard treatment (chemotherapy combined with immunotherapy).
Required: EGFR exon 19 deletion
EGFR (including 19del, L858R, S768I, L861Q, and/or G719X)
Required: EGFR L858R
EGFR (including 19del, L858R, S768I, L861Q, and/or G719X)
Required: EGFR S768I
EGFR (including 19del, L858R, S768I, L861Q, and/or G719X)
Required: EGFR L861Q
EGFR (including 19del, L858R, S768I, L861Q, and/or G719X)
Required: EGFR G719X
EGFR (including 19del, L858R, S768I, L861Q, and/or G719X)
Required: BRAF V600E
BRAF V600E
Required: NTRK1 fusion
NTRK
Required: NTRK2 fusion
NTRK
Required: NTRK3 fusion
NTRK
Required: MET exon 14 skipping mutation
MET14 exon skipping mutation
Required: RET fusion
RET
Required: ROS1 fusion
ROS1
Disease stage
Required: Stage IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy combined with immunotherapy — first line
Patients with negative driver genes must have received first line standard treatment (chemotherapy combined with immunotherapy).
Must have received: chemotherapy — after standard targeted therapy has failed
Patients with positive driver genes must have received at least one line chemotherapy after standard targeted therapy has failed.
Cannot have received: taxane (docetaxel)
Previously received treatment with docetaxel
Lab requirements
Blood counts
Hemoglobin ≥ 100 g/L (female), 110g/L (male); Neutrophil count ≥ 2×10^9/L; Platelet count ≥ 100×10^9/L
Kidney function
Creatinine ≤15mg/L or creatinine clearance rate (CrCl) ≥ 60mL/min (Cockcroft Gault formula)
Liver function
Total bilirubin ≤ 1.5x ULN; ALT and AST ≤ 3×ULN or ≤ 5×ULN (for patients with liver metastases); Albumin ≥ 30 g/L
Cardiac function
QTcF interval must be ≤ 480 ms (≤ 500 ms for patients with ventricular pacemakers)
Hemoglobin ≥ 100 g/L (female), 110g/L (male); Neutrophil count ≥ 2×10^9/L; Platelet count ≥ 100×10^9/L; Creatinine ≤15mg/L or creatinine clearance rate (CrCl) ≥ 60mL/min (Cockcroft Gault formula); Total bilirubin ≤ 1.5x ULN; ALT and AST ≤ 3×ULN or ≤ 5×ULN (for patients with liver metastases); Albumin ≥ 30 g/L; QTcF interval must be ≤ 480 ms (≤ 500 ms for patients with ventricular pacemakers)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06929936 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior taxane disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR exon 19 deletion is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR L858R is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify